Skip to main content
About
Back
Overview
Executive Management
Board of Directors
Corporate Governance
Products
Back
Overview
DuraGraft®
Krillase®
MATLOC™ Platform
Clinical
Back
Publications
DuraGraft Publications
MATLOC Publications
News
Back
2022
2021
Investors
Contact
Back
Contact Us
Sign Up
Language
Back
GER
NEWS
2021
2022
2021
List of articles in category 2021
Title
03.12.2021
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
03.12.2021
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
16.11.2021
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
04.03.2021
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
04.02.2021
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board
01.02.2021
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
14.01.2021
Marizyme Announces Approval for DuraGraft® in India
11.01.2021
Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf
07.01.2021
Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"
